News & Views

  • Dr Amy Beynon

UK/Chinese Collaboration to Develop Innovative Technologies for Epigenetic Analysis Announced

Dec 15 2017 Read 1616 Times

Porvair Sciences are teaming up with Suzhou Tianlong Bio Technology Co Ltd, together with Swansea University and Xi'an Jiaotong University in a collaborative project entitled, ‘Automating & Stratification of Epigenetics in Healthcare’ that is part of the Innovate UK/Jiangsu Industrial Challenge Programme.

The project will integrate Porvair's innovative solid-state chromatin immunoprecipitation platform, Chromatrap® with Tianlong's expertise in automated robotic technologies and diagnostic multiplex PCR kits to develop innovative technologies in epigenetic characterisation for patient stratification in renowned precision medicine. Academics in cancer epigenetics from Swansea University and Xi'an Jiaotong University will support the project by providing insights and direction for the application in cancer research and drug development.

Dr Amy Beynon, Technical and Business Development Manager at Porvair Sciences said: “Developing new technologies to simplify and advance epigenetics research is the driving force here at Porvair. Combining Chromatrap with Tianlong's expertise in diagnostic multiplex arrays, we will provide a streamlined workflow across both research and clinical applications. The ultimate collaborative goal is to provide innovative tools that improve diagnostic options for patients and informed novel stratified therapeutics.”

The project will provide an excellent opportunity for Porvair Sciences and Tianlong to develop an automated ChIP assay that enables users to perform chromatin isolation straight through to multiplex PCR, completely hands-free. Researchers and diagnostic laboratories will be able to simultaneously analyse multiple epigenetic marks using less material and obtain better quantitative analyses. Diagnostic multiplex arrays are currently available for a number of cancer disease states, but application in breast and ovarian cancers is non-existent which greatly impacts the development of novel therapeutics.

Dr Lindsay Parkes a Senior Research Scientist at Porvair Sciences emphasised that "the opportunity to be the first to provide fundamental technologies for precision medicine, starting with breast and ovarian cancer, we can begin to shed light on the underlying epigenetics processes in cancer biology and take the first steps in developing therapeutics solutions for patients."

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.


Digital Edition

International Labmate Buyers Guide 2018

June 2018

In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...

View all digital editions

Events

INTERPHEX JAPAN 2018

Jun 27 2018 Tokyo, Japan

PREP 2018

Jul 08 2018 Baltimore, MD, USA

AACC Annual Meeting & Clinical Lab Expo 2018

Jul 29 2018 Chicago, IL, USA

HPLC 2018

Jul 29 2018 Washington DC, USA

M&M 2018

Aug 05 2018 Baltimore, MD, USA

View all events